Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune‐checkpoint inhibitor‐related biomarkers

Abstract Background Advanced penile squamous cell carcinoma (pSCC) is a rare and aggressive malignancy with limited success of immune-checkpoint inhibitors (ICIs). Approximately half of pSCC cases are associated with human papillomavirus (HPV) infection. Methods Evaluation was done retrospectively of the landscape of somatic alterations and ICI-related biomarkers in pSCC by using the Caris Life Sciences… Continue reading Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune‐checkpoint inhibitor‐related biomarkers

Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune‐checkpoint inhibitor‐related biomarkers

Penile squamous cell carcinoma (pSCC) is a rare and aggressive malignancy with limited success of immune-checkpoint inhibitors (ICIs) Half of pScc cases are associated with human papillomavirus (HPV) infection . HPV16/18+ tumors were exclusively found to be the most common mutations . Increased tumor mutational burden could serve as a biomarker for predicting therapeutic response… Continue reading Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune‐checkpoint inhibitor‐related biomarkers

Look Who’s Talking: How Electrical Communication Drives Melanoma 

It sounds like something out of Frankenstein, but a new study in the AACR journal Cancer Discovery suggests that changes in electrical signals could spark cancer in certain skin cells.  Researchers found that the transfer of a neurotransmitter between two types of skin cells dampened electrical activity in the receiving cell and triggered the growth… Continue reading Look Who’s Talking: How Electrical Communication Drives Melanoma 

Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer

In lung cancer, overexpression of nuclear export proteins can result in inactivation of critical tumor suppressor proteins and cell-cycle regulators . Selinexor in combination with pembrolizumab demonstrated promising antitumor activity in patients with mNSCLC . The therapy-related toxic effects were consistent with the prior safety data for both drugs .

Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer

In lung cancer, overexpression of nuclear export proteins can result in inactivation of critical tumor suppressor proteins and cell-cycle regulators . Selinexor in combination with pembrolizumab demonstrated promising antitumor activity in patients with mNSCLC . The therapy-related toxic effects were consistent with the prior safety data for both drugs .